Jefferies Downgrades Astria Therapeutics (ATXS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ATXS Hot Sheet
Price: $12.58 --0%
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Jefferies analyst Eun Yang downgraded Astria Therapeutics (NASDAQ: ATXS) from Buy to Hold with a price target of $13.00 (from $30.00).
For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.
Shares of Astria Therapeutics closed at $8.47 yesterday.
You May Also Be Interested In
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
- Cinemark Holdings (CNK) PT Raised to $45 at StoneX
- Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
